Encouraging Outcomes from Medivir's Clinical Trial
Medivir AB has recently unveiled promising findings from its ongoing phase 1b/2a open-label trial involving fostroxacitabine bralpamide (fostrox) combined with Lenvima for patients dealing with advanced liver cancer. This combination therapy has shown better results for individuals undergoing second-line treatment. In the study, the median time to progression (TTP) was reported at 10.9 months, which greatly exceeds the standard TTP of 3 to 4 months generally seen with conventional treatment options.
Key Insights from the Study
Response Rates and Durability
The trial results show that 24% of participants achieved an objective response rate (ORR), with those responding maintaining a median duration of response of 7.0 months. Remarkably, 19% of patients continued their treatment for more than a year, and one individual remained on treatment for over two years. These sustained responses underscore the potential effectiveness of this therapy across diverse patient backgrounds.
Safety and Tolerability Profile
Beyond its encouraging response rates, the safety profile of this combination therapy also looks promising. Only one participant discontinued fostrox due to adverse events, indicating strong tolerability. While some common hematological adverse effects occurred, they were temporary, allowing for ongoing treatment without serious issues. Importantly, there were no reported cases of febrile neutropenia or significant platelet deficiencies linked to fostrox.
Understanding Fostrox's Mechanism of Action
Fostrox, Medivir's leading product, is a distinctive oral therapy aimed at targeting liver cancer at the cellular level. Its innovative mechanism allows it to deliver a potent chemotherapy agent directly to liver tumor cells, reducing damage to the surrounding healthy tissue. This focused approach could mark a significant advancement in how oncology treatments are delivered.
Looking Ahead: Future Trials
With the promising data presented at the ESMO Congress, Medivir is ready to progress to the next phases of clinical evaluation. They are currently preparing for a phase 2b trial, which will compare the efficacy of the fostrox and Lenvima combination against Lenvima on its own. This randomized trial has the potential to offer further insights into the advantages of this hopeful treatment strategy for patients battling liver cancer.
About Liver Cancer and Medivir
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for more than 80% of liver cancer cases worldwide, and resulting in roughly 660,000 diagnoses each year. This disease tends to be particularly aggressive, often showing survival rates of less than 20% over five years. Medivir AB is committed to developing innovative cancer therapies that address unmet medical needs, focusing primarily on liver-related cancers like HCC. The company is listed on Nasdaq Stockholm under the ticker MVIR.
Frequently Asked Questions
What is fostrox and how does it work?
Fostrox is an oral treatment specifically designed to deliver chemotherapy to liver tumor cells, aiming to spare healthy cells from damage.
What were the key results from the recent trial?
The trial indicated a median TTP of 10.9 months and an ORR of 24%, highlighting the effectiveness of the combination of fostrox and Lenvima.
How does the safety profile of fostrox compare to other treatments?
The safety profile seems favorable, with minimal discontinuations due to adverse effects and no severe issues like febrile neutropenia reported.
What are the next steps for Medivir?
Medivir is preparing to launch a phase 2b trial to examine how the combination of fostrox and Lenvima compares to Lenvima alone.
Why is this research significant?
This research is important because it offers hope for patients with advanced liver cancer, especially those who haven't responded to available treatments.
